May 2021 Price Concessions 1st Update

THIS CONTENT HAS NOW EXPIRED

The Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions:

Drug Pack Size Price Concession
Candesartan 2mg tablets 7 £1.35
Chlorpromazine 50mg tablets 28 £15.98
Eplerenone 25mg tablets 28 £14.25
Eplerenone 50mg tablets 28 £26.30
Esomeprazole 20mg gastro-resistant tablets 28 £5.18
Etoricoxib 60mg tablets 28 £12.00
Naftidrofuryl 100mg capsules 84 £8.10
Olmesartan medoxomil 10mg tablets 28 £7.85
Olmesartan medoxomil 20mg tablets 28 £8.30
Olmesartan medoxomil 40mg tablets 28 £14.52
Pregabalin 100mg capsules 84 £6.10
Pregabalin 150mg capsules 56 £4.99
Pregabalin 200mg capsules 84 £7.00
Pregabalin 300mg capsules 56 £5.61
Pregabalin 50mg capsules 84 £6.69
Pregabalin 75mg capsules 56 £6.50
Prochlorperazine 5mg tablets 28 £1.79
Sulfasalazine 500mg gastro-resistant tablets 112 £18.79
Sulfasalazine 500mg tablets 112 £17.45
Trimethoprim 200mg tablets 6 £1.70
Trimethoprim 200mg tablets 14 £3.97
Trimethoprim 50mg/5ml oral suspension sugar free 100ml £11.95
Zonisamide 100mg capsules 56 £49.99

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated May 2021 Drug Tariff price. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.

If you have problems obtaining a Part VIII product at the stated Drug Tariff price, please report the issue using the online feedback form on the PSNC website. Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.

Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. 

 

FINAL CALL: Tell us more about the challenges your pharmacy team is facing to create powerful evidence to put to policy makers.

Click Here